I N T R O D U C T I O N
Anaemia develops in most patients with chronic kidney disease (CKD) [1] , for whom treatment with erythropoiesisstimulating agents (ESAs) represents one of the most significant advances in therapeutic management. Prior to ESA use, frequent transfusions were required, with their associated risks of viral transmission, hypersensitization or haemochromatosis [2] . Several observational studies have shown that severe anaemia in haemodialysis (HD) patients is related to increased morbidity, and mortality [3] [4] [5] . Conversely, reversing anaemia in HD patients can ameliorate ventricular hypertrophy [6, 7] , reduce mortality and the risk of hospitalization [8, 9] , and improve the quality of life [9, 10] .
The initial guidelines for treating anaemia in CKD established a haemoglobin target exceeding of 11 g/dL [11] , which necessitated increased ESA administration/prescription [12] [13] [14] . However, some patients showed ESA hypo-responsiveness and failed to reach their target haemoglobin levels, despite increasing their ESA doses. These patients manifest an increased risk of adverse events including hypertension, stroke, vascular thrombosis and all-cause mortality [15] [16] [17] [18] [19] . The underlying mechanisms of this increased risk remain obscure, with some hypotheses suggesting a direct effect of the haemoglobin itself, while others have implicated indirect effects from high levels of iron, platelet dysfunction or hypertension [20, 21] . Factors that influence ESA hypo-responsiveness and the subsequent need for higher doses of ESAs include iron deficiency, severe hyperparathyroidism, low-serum albumin and high C-reactive protein (CRP; both indicative of inflammation), malnutrition, elevated aluminium levels, dialysates contaminated by chloramines and other oxidants, suboptimal dialysis, and medications such as angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and statins [15, 16, [22] [23] [24] [25] . Some of these factors are themselves associated with a higher mortality in HD patients.
High-dose ESA administration has been associated with elevated mortality in both observational and randomized controlled studies [12, 19] , but it remains unclear whether the dose itself impacts clinical outcome, or simply reflects comorbidities and/or a malnutrition-inflammation complex syndrome. This study aimed to explore the relationships between ESA dose and mortality in a large cohort of incident Spanish HD patients, adjusted for haemoglobin levels and other factors affecting ESA hypo-responsiveness, together with additional potential confounders. Our objective was to evaluate whether high doses of ESA are intrinsically harmful.
M A T E R I A L S A N D M E T H O D S

Patients and study design
The objectives of this study were to evaluate the relationships between ESA dose, mortality and hospitalization in incident HD patients. A multicentre, retrospective observational project was designed to collect these correlates. A total of 1679 adult incident HD patients treated with ESAs in 59 Spanish Fresenius Medical Care (FMC) clinics between July 2011 and September 2014 were enrolled ending the follow-up period on 31 December 2016. Less than 90 days before study enrollment of any renal replacement therapy (i.e. peritoneal dialysis or transplantation) was mandatory prior to the commencement of the observation period. Exclusion criteria included patients who failed to remain in the study for at least 90 days (baseline), and patients for whom the type of vascular access (VA) was not preserved for at least 75% of the dialysis sessions during the observation period. This criterion was established in an effort to control the confusion created by this covariate due to the relationship between type of VA and outcome [26] .
All included patients signed a consent form authorizing the use of their clinical data for research. Data were extracted from EuCliD V R , the FMC clinical data system that had been previously validated [27] . Age, gender, Charlson comorbidity index (CCI) and body mass index (BMI) data were collected as demographic variables. Different HD clinical parameters were selected including Kt/V, Kt (in L), effective treatment time [(Td) in min] and type of VA, i.e. central venous catheter (CVC) or native arterio-venous fistula (AVF). Finally, analytic laboratory data related to the main project outcome were selected. These included haemoglobin, ferritin, transferrin saturation (TSAT) index, erythropoietin resistance index (ERI), albumin and CRP. Patients were monitored until death or their curtailed use of the FMC clinic (for any reason). The various causes of death and hospitalization and dates were obtained from the attending nephrologists, through proper usage of the codes from the International Classification of Diseases and which are registered in EuCliD database.
The main project variable was weekly ESA dose. Due to the heterogeneity of ESAs, doses were directly adjusted to IU values for alpha and beta erythropoietin, and bio-similar compounds, using the conversion factor, 1 mg ¼ 200 IU for Aranesp V R . IU conversion was as per the manufacturer's instructions for Mircera V R . In addition, intravenous iron (FeIV) doses (mg/ month) were collected. Both ESA and FeIV administration were governed by standard medical practice in accordance with the KDIGO and EBPG guidelines for treating anaemia [28, 29] ; these data were presented as average drug prescriptions for each patient during the baseline period.
All HD sessions were performed using 4008 S or 5008 (FMC) monitors with a dialysis dose targeted as Kt/V !1.4 and Td !240 min per session. Patients were dialysed with single use of Fresenius Polysulfone Helixone dialysers (1.4 to 1.8 m 2 ) using ultrapure dialysate, without aluminium, chloramines or other oxidants.
Statistical analysis
Data are presented as: mean values 6 standard deviation (SD) for normally distributed variables, medians with interquartile range (25th-75th percentile) for non-normally distributed variables, percentages (%) for categorical variables. Demographic features, laboratory analytical values and HD parameters were compared across ESA dose quintiles using the Chi-square test for categorical factors and ANOVA for continuous variables. Substantially (positively) skewed variables were analysed using the Kruskal-Wallis test.
To evaluate the relationships between ESA and mortality, Kaplan-Meier survival curves according to ESA quintile were estimated and compared by the log-rank test. Cox regression was used to calculate the corresponding hazard ratios (HRs) with 95% confidence intervals (CI) for all-cause mortality, using the ESA lower dose quintile as reference. In addition, different multivariate COX models were generated and then added sequentially as covariables. The models were designated as: (i) adjusted for demographics: age (years), CCI, VA, gender and BMI (km/m 2 ) data were added to the univariate model; (ii) case-mix adjusted model: TSAT (%), CRP (mg/L), haemoglobin (g/dL), Kt (L) and FeIV dose (mg/month) data were added to the demographics-adjusted model; (iii) adjusted: serum albumin (g/dL) data was added to the case-mix adjusted model. This stepwise modelling scheme was also performed to assess cardiovascular (CV) and oncologic mortality.
In addition to the conventional methods for the survival analysis mentioned above, an additional approach considering a competing risks scenario between the different endpoints (renal transplantation, transferred patient or lost to follow-up) was performed. Subsequently, we constructed several adjusted competing risks regression models to calculate the corresponding sub-distribution hazard ratios (SHRs) for all-cause mortality following the approach proposed by Fine and Gray [30] . Finally, we used this methodology to study CV mortality considering the other causes of death as a possible competing outcome.
To assess the relationship between ESA dose and hospitalization risk, multivariate logistic regression analyses were performed using the same sequential modelling pattern (i.e. univariate, demographics-adjusted, case-mix adjusted and adjusted). This modelling strategy was also used to define the relationship between ESA dose and the risk of multiple hospitalizations (during follow-up), hospitalization due to infectious disease, VA or CV events.
To optimize data outputs, the potential non-linear effects of risk factors were explored using several univariate models. Cutoff values were chosen to generate balanced groups in a clinically relevant fashion. The chosen cut-off values were age All analyses were performed on an intention-to-treat basis. Moreover, several comparisons across the ESA quintiles established during the baseline period were repeated to compare haemoglobin levels and ESA dose at 3 and 6 months of follow-up. Further adjusted survival curves for ESA dose and the haemoglobin levels were performed using the variables recorded at the baseline and 6 months as a new baseline. We used propensity score matching (PSM) to minimize the reverse causality phenomena. Thus, we calculated the propensity score for each patient by modelling the probability of receiving an ESA dose of > or 8000 IU/week using logistic regression models. This cut-off value was selected for its clinical relevance following consideration of the highest ESA dose quintile. The resulting propensity scores were used to match the groups using a 1:1 ratio, using a calliper fixed as 0.2 of the pooled SD of the logit of the propensity scores [31] . To examine the quality of matching, we evaluated the balance in the covariates using the standardized differences before and after matching, considering that differences <0.1 were negligible imbalance [32] and also by performing the corresponding bivariate comparisons.
All statistical tests were performed using SPSS v.23, except for PSM analyses, which were performed using an R-Menu for SPSS [33] , and the Fine and Gray competing risks regression models, which were performed using the 'CMPRSK' package [34] , based on the R statistics software version 3.1.1. P < 0.05 was considered to be statistically significant.
R E S U L T S
Baseline characteristics
Our patient cohort had a mean age of 68.23 6 13.50 years, an average CCI of 5.62 6 1.97 and 34.96% of them were female. Alpha and beta erythropoietin or bio-similar compounds, were used in 51.43% of the patient cohort. A total of 44.76% of patients were treated using Aranesp V R and only 3.78% of the entire cohort was treated using Mircera V R . The median (interquartile range) ESA dose for the alpha and beta erythropoietin group was 5261.14 (3423.3-7373.27) UI/week, for the Aranesp V R it was 4692.78 (3147.21-6908.33) and for the Mircera V R group it was 6533.1 (4536.01-11049.25). There were significant differences between groups (P ¼ 0.001).
Demographic features, analytical (laboratory) data and HD parameters were compared across ESA quintiles (Table 1) . For these comparisons, neither age nor CCI were statistically different. However, quintiles defined by higher ESA doses (versus lower) manifested a higher percentage of female patients, CVCs and patients with a lower BMI. Regarding laboratory parameters, progressive and significant decreases in albumin and haemoglobin levels were observed across quintiles (from Q1 to Q5). Conversely, the CRP and the ERI levels showed a significant increase from Q1 to Q5. Finally, comparisons for the different clinical HD parameters showed statistically significant changes in Td, but not Kt (Table 1) ; these findings were likely BMI related. FeIV administration was found to be higher in those groups with higher ESA doses.
Survival and hospitalization
Patients were monitored until death or until they abandoned the study. The mean follow-up time was 27.70 6 15.06 months. A total of 1010 patients left the study, typically for kidney transplantation (n ¼ 334), switching dialysis unit (n ¼ 248) or for other causes (n ¼ 16). There were 412 deaths during the observation period, principally due to CV disease (41.02%), sudden death (11.89%), infectious disease (13.35%), gastrointestinal disease (5.10%), oncological causes (8.25%) and other causes (20.39%). In the entire cohort, the corresponding Kaplan-Meier survival curves to study the mortality profiles between different ESA compounds resulted non-significant (Log-rank ¼ 1.35; P ¼ 0.510). On the contrary, Kaplan-Meier survival curves across quintiles were significantly worse in patients with higher ESA doses (Log-rank test ¼ 71.44; P < 0.001; Figure 1 ). Among the study participants, 998 (59.44%) underwent a total of 2437 hospital admissions during follow-up, primarily due to infections (23.26%), CV (23.18%) or VA-related events (16.43%).
We built several univariate cox regression models and logistic regression models to identify predictors of mortality and hospitalization among the parameters recorded. Different multivariate regression models were then built sequentially using the significant variables explored in the previous univariate modelling strategy to determine how ESA dose could constitute an independent predictor of mortality and hospitalization (Figure 2) .
The highest (5th) ESA quintile (>8127.4 IU/week) was identified as an independent predictor for all-cause mortality (adjusted model; HR ¼ 1.627; 95% CI 1.13-2.35; P ¼ 0.009; Figure 2 ) and CV mortality (adjusted model; HR ¼ 2.388; 95% CI 1.32-4.29; P ¼ 0.004; Figure 2 ) versus the first quintile.
Conversely, ESA dose was neither an independent predictor of oncological mortality (adjusted model; HR ¼ 3.049; 95% CI 0.84-11.14; P ¼ 0.092), nor of infectious mortality (adjusted model; HR ¼ 0.996; 95% CI 0.35-2.85; P ¼ 0.96). We performed a sensitivity analysis introducing in to the Cox models the regions for the different units where the patients were treated as a frailty variable. There were no significant differences between clinics, which is consistent with the idea that all the units used the same medical practice protocol marked by the provider. In the results of this multivariate analysis again the highest (5th) ESA quintile was identified as an independent predictor for all-cause mortality (HR ¼ 1.489; 95% CI 1.02-2.17; P ¼ 0.039). Moreover, an ESA dose comprising between 2837.8 and 4262.6 IU was isolated as a protective mortality predictor (HR ¼ 0.665; 95% CI 0.45-0.98; P ¼ 0.043). Also, haemoglobin levels <10 g/dL (HR ¼ 2.567; 95% CI 1.73-3.83; P < 0.001) or >12 g/dL (HR ¼ 1.497; 95% CI 1.09-2.04; P < 0.001) were isolated as mortality predictors.
The project was conducted in a multiple competitive risk scenario because it was developed in a routine clinical practice landscape. Therefore, several adjusted competing risk regression models were generated (Figure 3) . Again, the highest (5th) ESA quintile (>8127.4 IU/week) was identified as an independent predictor for all-cause mortality (SHR ¼ 1.558; 95% CI 1.17-1.94; P ¼ 0.024) and CV mortality (SHR ¼ 2.615; 95% CI 2.00-3.22; P ¼ 0.002).
In terms of hospitalization, logistic regression revealed that the highest ESA quintile constituted an independent predictor of hospitalization for some reason [adjusted model; odds ratio FIGURE 1: Kaplan-Meier survival curves according to ESA dose quintiles. Corresponding survival tables are shown. P-values were calculated using the log-rank test.
ESA dose and mortality in HD patients (OR) ¼ 2.092; 95% CI 1.46-3.00; P < 0.001; Figure 2 ], as well as CV (adjusted model, OR ¼ 1.906; 95% CI 1.24-2.92; P ¼ 0.003; Figure 2 ) and infectious disease (adjusted model, OR ¼ 1.63; 95% CI 1.02-2.58; P ¼ 0.041), but not VA (crude model; OR ¼ 1.61; 95% CI 0.99-2.59; P ¼ 0.054).
We then analysed patients' haemoglobin levels, together with ESA doses 3 and 6 months after the baseline period, excluding patients who died or had been censored within the first 6 months. These descriptive results are similar to those reported for the full patient cohort. Parameters across the quintiles remained stable over time. Further adjusted survival curves using the baseline and 6-month follow-up (i.e. post-baseline) parameters were calculated for the ESA and haemoglobin levels ( Figure 4) . Again, the highest ESA quintile dose (>8127.4 IU/ week) was identified as an independent predictor for all-cause mortality (HR ¼ 1.646; 95% CI 1.06-2.55; P ¼ 0.027). The haemoglobin baseline models were significant for haemoglobin levels <10 g/dL (HR ¼ 2.425; 95% CI 1.66-3.54; P < 0.001) or >12 g/dL (HR ¼ 1.364; 95% CI 1.01-1.85; P ¼ 0.047).
PSM analyses (baseline characteristics pre/post PSM are shown in Table 2 ) revealed that in the adjusted cohort, ESA doses >8000 IU/week constituted an independent predictor of all-cause mortality (HR ¼ 1.47; 95% CI 1.11-1.94; P ¼ 0.007; þ P < 0.01; and *P < 0.05; no symbol indicates no significant difference. Figure 5 ). Moreover, for the all-cause hospitalization analysis, logistic regression models in the PSM-adjusted cohort confirmed our previous risk analyses (OR ¼ 1.510; 95% CI 1.07-2.13; P ¼ 0.019).
D I S C U S S I O N
In this analysis, we observed a dose-dependent relationship showing that higher ESA doses were associated with a higher mortality risk, despite adjustments for several confounders, including haemoglobin, or covariates related with the ESA hypo-responsiveness. These findings were subsequently confirmed using PSM analyses that showed unambiguously that patients receiving ESA >8000 IU/week displayed a higher mortality risk. Moreover, a high ESA dose was associated with an increased risk for all-cause hospitalization.
The main question was to address the intrinsic toxicity of ESAs (i.e. are ESAs harmful?). Given the absence of randomized studies, statistical data are instead required to address this issue. Streja et al. [35] , using marginal structural models to examine causality, ESA dose and mortality, concluded that a high ESA dose might be causally associated with excessive mortality. The Netherlands Cooperative Study on the Adequacy of Dialysis used a sequential Cox approach and inverse probability of censoring weights (IPCW) to conclude that patients with ESA doses >6000 IU/week have a 1.2-1.5 increased mortality risk [36] . Koulouridis et al. [19] conducted a meta-analysis using the data from 31 trials and reported that a higher ESA dose was correlated with all-cause mortality, irrespective of the haemoglobin levels.
A second unanswered question was which of the two parameters, ESA dose or hypo-responsiveness, could best predict mortality? There are strong relationships between patient comorbidity, ESA requirements and variation in haemoglobin level over time [17, [37] [38] [39] [40] [41] . There are also multiple causes of hypo-responsiveness that include iron deficiency, chronic hyperparathyroidism, CVC [and its associations with increased blood loss or subclinical inflammation (also linked with lowserum albumin)], aluminium toxicity and (other) water contaminants, malnutrition, suboptimal dialysis, ACEI, ARB and statin use [16, 22, 23] . Some authors have stated that ESA responsiveness, rather than dose, is the major determinant of adverse events in HD patients [16, 39] .
The ERI indicates the degree of responsiveness to ESAs; it can be easily calculated and managed, and is directly related to mortality. However, this index has several limitations. First, the ERI is strongly (linearly) related to ESA dose and weight [41] . Secondly, modifying the ESA dose changes the ERI, unless there has been a change in the mechanism of resistance. Thirdly, the route and frequency of ESA administration will impact the ERI. Fourthly, increased haemoglobin levels, independent of ESA administration, may not be associated with a higher mortality risk [42] [42] , with any fluctuations in ERI more closely related to the treatment pattern than resistance to ESAs. In our study, most ESA hypo-responsiveness-related factors have been statistically adjusted. Moreover, the PSM model includes BMI and haemoglobin as underlying components of the ERI calculation. Thus, overall, our data would suggest that ESA dose might be a better predictor of mortality.
There is no well-established haemoglobin target level in HD patients. Low concentrations of haemoglobin are associated with an increased mortality risk [18] , but reaching optimal haemoglobin concentrations necessitates a high ESA dose. While the causal relationship between ESA and mortality has been debated, the ideal ESA dose remains undetermined. Moreover, the intended haemoglobin target influences the ESA dose. In Spanish FMC clinics, the haemoglobin target is $10-12 g/dL when using ESAs. Further, ESA doses are continually falling over time as haemoglobin targets are updated (as per international guidelines), stricter controls for blood loss (during HD treatment) are applied and dialysis doses are increased [43] .
Given the assumption that high ESA doses correlate with increased mortality, we should determine which ESA doses are problematic. Kwon et al. [18] stipulated that an ESA dose >126 IU/kg/week was associated with a haemoglobin level <10 g/dL, which increased the risk of mortality. In the ANSWER study [15] , an ESA dose >16 000 IU/week increased mortality (HR ¼ 1.62). Streja et al. [35] also showed that ESA doses of between 18 000 and 24 000 IU/week increased the mortality risk (HR ¼ 1.17). In the Suttorp et al. study [36] , a comparison of patients administered > or 6000 IU/week resulting in HR values of 1.2 with a Cox and versus 1.54 with a marginal structural model (MSM). In our study, administration of more than 8000 IU/week is associated with a higher mortality versus the lower mean ESA dose in our population. In this study, we describe ESA dose in terms of IU/week rather than IU/kg/week. In Spain, and elsewhere, nephrologists adjust weekly doses without correction for body weight [16] [17] [18] [19] 36] . We should however note that BMI was introduced in the regression models. Another factor to consider is the route of administration and type of ESA used [44] . In this study, the intravenous route was used exclusively and there were not significant differences in mortality between the different ESA compounds (Logrank ¼ 1.35; P ¼ 0.510).
How might the administration of ESAs increase the risk of CV-related mortality? Some CV events have been correlated to high ESA dose. These include hypertension, stroke and thrombotic events [19, [45] [46] [47] [48] [49] . High-dose ESA-treated patients with higher target haemoglobin levels, and poorly controlled hypertension, manifest a high risk of mortality [46] , with a direct ESA effect proposed to be causal [11] . Potential mechanisms of ESAinduced hypertension have been proposed [47] including enhanced vascular responsiveness to vasoconstrictors [48, 49] . Treatment with exogenous ESAs produces a rapid peak in ESA serum concentration post-injection that can induce vascular and cardiac changes. A similar association between ESA dose and an increased risk of stroke has been described, particularly in patients with poorly controlled hypertension, or in those with a prior history of stroke [19] . A high ESA dose may directly lead to thrombocytosis [50] , which may also explain the association between ESA dose and the increased risk of thrombotic events [19] . Despite the suspicion of increased cancer progression reported in several studies, we did not detect any correlation between high ESA dose and an increased risk of oncological mortality [51] . This finding was consistent with our data for higher CV-linked hospitalization, mortality risk and ESA dose. Additionally, the use of CVCs provides a plausible explanation for increasing blood loss and the need for ESA administration. In our study, the distribution of the different types of VA among the ESA quintiles is consistent with this notion. Moreover, CVC use necessitates good patency to perform the HD treatment and assumes concomitant increases in inflammation, infection and hospitalization [26, 35] . Our analyses identified a high ESA dose as an independent predictor of all-cause mortality and infectious hospitalization, but not VArelated hospitalization, even when including VA as a confounding factor in the Cox models or PSM analyses.
Our study has both strengths and limitations. The strengths were that we included a large sample size of incident HD patients in a multicentre study. Moreover, we tried to make adjustments throughout the different regression models to resolve the reverse causality phenomenon and we tried to deal with the bias by indication problem using the PSM method. However, in our cohort, predominantly Caucasian, the estimated regression coefficients may be biased and some residual confounding factors might have remained such as thrombocytosis and poorly controlled blood pressure not directly evaluated in our data base. Also, the CCI was used as a comorbid scale but this may not necessarily mean that the resulting groups were similar in terms of particular types of comorbidities. Moreover, due to the observational nature of the study we cannot establish causality.
Additionally, the intention of treatment design did not cover the various possible ESA requirements across the observation period. Therefore, a longitudinal observation period might be necessary to evaluate the full impact of ESA dosing over the outcomes.
Despite the fact that ESA dosing management for the patients studied here was governed by the medical practice fixed for only one HD service provider in one country, and there were no differences in mortality between the different regions analysed, different ESA formulations were analysed constructing equivalent UI doses. To overcome this limitation, the study design excluded patients of <90 day duration of HD treatment. Further, we re-evaluated the main variables after a further 3-and 6-month inclusion period for each patient, and obtained comparable results.
In conclusion, our data suggest that an ESA dose of >8000 IU/week for HD patients is associated with an increased risk of all-cause mortality and hospitalization and constitutes an independent risk factor. Further, randomized controlled trials are urgently needed to clarify the current landscape of ESA management in incident HD patients.
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